Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 1.00 |
| ▸ | BCHE | P06276 | 11/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 0.62 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533689 | 1.00 | ACHE (1.00) | ACHEBCHEFAAHMARK4NPY5R | |
| SCHEMBL533690 | 1.00 | ACHE (1.00) | ACHEBCHEFAAHMARK4NPY5R | |
| SCHEMBL12557213 | 1.00 | ACHE (1.00) | ACHEBCHEFAAHMARK4NPY5R | |
| Sulfuric Acid SCHEMBL533722 | 0.96 | ACHE (0.91) | ACHEBCHEFAAHMARK4NPY5R | |
| Succinic Acid SCHEMBL533895 | 0.96 | ACHE (0.91) | ACHEBCHEFAAHMARK4NPY5R | |
| Fumaric Acid SCHEMBL533727 | 0.94 | ACHE (0.89) | ACHEBCHEFAAHMARK4NPY5R | |
| Fumaric Acid SCHEMBL533726 | 0.94 | ACHE (0.89) | ACHEBCHEFAAHMARK4NPY5R | |
| SCHEMBL12798745 | 0.85 | ACHE (0.74) | ACHEBCHEFAAHMARK4MAOA | |
| SCHEMBL12208521 | 0.85 | ACHE (0.74) | ACHEBCHEFAAHMARK4NPY5R | |
| SCHEMBL12208527 | 0.84 | ACHE (0.72) | ACHEBCHEFAAHMARK4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251175-A1 | Stigmine Conjugates for Substance Use Disorders | COLUCID PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110251175-A1 | Stigmine Conjugates for Substance Use Disorders | COLUCID PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| WO-2010115124-A2 | COMPOSITIONS OF CHOLINESTERASE INHIBITORS | COLUCID PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100256229-A1 | COMPOSITIONS OF CHOLINESTERASE INHIBITORS | COLUCID PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256229-A1 | COMPOSITIONS OF CHOLINESTERASE INHIBITORS | COLUCID PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2010009316-A1 | STIGMINE CONJUGATES FOR SUBSTANCE USE DISORDERS | COLUCID PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090048229-A1 | Methods for promoting wakefulness | COLUCID PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090048229-A1 | Methods for promoting wakefulness | COLUCID PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| WO-2009011901-A2 | METHODS FOR PROMOTING WAKEFULNESS | COLUCID PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251175-A1 | Stigmine Conjugates for Substance Use Disorders | TACR2, NPSR1, TACR3 | ACHE 44/4885BCHE 71/4885FAAH 164/4885 |
| US-20100256229-A1 | COMPOSITIONS OF CHOLINESTERASE INHIBITORS | ACHE, BCHE, CES1 | ACHE 1/4885BCHE 2/4885FAAH 146/4885 |
| US-20090048229-A1 | Methods for promoting wakefulness | HCRTR2, HCRTR1, CHAT | ACHE 107/4885BCHE 85/4885FAAH 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.